This molecular characterization provided a strong rationale for targeted therapies in T-ALL, such as drugs directed against JAK, NOTCH1, BCL-2 or PI3-AKT signaling pathways. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.